Genedrive (GB:GDR) has released an update.
Genedrive PLC has announced the first UK commercial sale of its Genedrive CYP2C19-ID Kit following NICE’s recommendation for CYP2C19 genotyping to guide clopidogrel treatment after strokes. The initial order, valued at approximately £0.1M, will support an implementation assessment at Greater Manchester’s Comprehensive Stroke Centre. This milestone in Genedrive’s commercialization strategy is expected to contribute to improved patient outcomes and potential NHS savings of up to £454M over five years.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
